Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 2095116-40-6 Chemical Structure| 2095116-40-6

Structure of Brigimadlin
CAS No.: 2095116-40-6

Chemical Structure| 2095116-40-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Brigimadlin (BI 907828) is an orally active E3 ubiquitin ligase MDM-2 inhibitor that blocks MDM-2's negative regulation of the tumor suppressor p53. It is suitable for antitumor research.

Synonyms: BI 907828

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Brigimadlin

CAS No. :2095116-40-6
Formula : C31H25Cl2FN4O3
M.W : 591.46
SMILES Code : O=C(C1=C(C)C2=NN3C(C[C@@](N4CC5CC5)([H])[C@]3([H])[C@H](C6=CC=CC(Cl)=C6F)[C@@]74C(NC8=C7C=CC(Cl)=C8)=O)=C2C=C1)O
Synonyms :
BI 907828
MDL No. :N/A

Safety of Brigimadlin

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300-H360-H372-H413
Precautionary Statements:P260-P264-P270-P273-P280-P321-P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06619509 Solid Tumours PHASE2 RECRUITING 2036-12-31 Sanatorio Finochietto, Caba, C... More >>1120AAB, Argentina|Prince of Wales Hospital-Randwick-66496, Randwick, New South Wales, 2031, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Brussels - UNIV Saint-Luc, Bruxelles, 1200, Belgium|UZ Leuven, Leuven, 3000, Belgium|H.S.J. Beneficência Portuguesa - S?o Paulo, Sao Paulo, 01323-001, Brazil|West China Hospital, Chengdu, 610041, China|Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China|Copenhagen University Hospital, Rigshospitalet, K?benhavn ?, 2100, Denmark|Helios Klinikum Berlin-Buch, Berlin, 13125, Germany|Universit?tsklinikum Frankfurt, Frankfurt, 60590, Germany|Universit?tsklinikum Tübingen, Tübingen, 72076, Germany|Clinexpert Gyongyos, Gyongyos, 3200, Hungary|Sourasky Medical Center, Tel-Aviv, 6423906, Israel|Nagoya University Hospital, Aichi, Nagoya, 466-8560, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, 811-1395, Japan|Kyushu University Hospital, Fukuoka, Fukuoka, 812-8582, Japan|Tohoku University Hospital, Miyagi, Sendai, 980-8574, Japan|Okayama University Hospital, Okayama, Okayama, 700-8558, Japan|Osaka International Cancer Institute, Osaka, Osaka, 541-8567, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, 104-0045, Japan|Oncology Center-Maria Sklodowska-Curie Institute, Warsaw, 02-781, Poland|Hospital Duran i Reynals, L'Hospitalet de Llobregat, 08907, Spain|Fundación Jiménez Díaz, Madrid, 28040, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|Hospital Clínico de Santiago, Santiago de Compostela, 15706, Spain|Karolinska Comprehensive Cancer Center, Stockholm, 171 76, Sweden|The Royal Marsden Hospital, Chelsea, London, SW3 6JJ, United Kingdom Less <<
NCT03449381 Neoplasms PHASE1 ACTIVE_NOT_RECRUITING 2025-06-30 Sarcoma Oncology Center, Santa... More >> Monica, California, 90403, United States|Yale University School of Medicine, New Haven, Connecticut, 06511, United States|Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, 34232, United States|Norton Cancer Institute, Downtown, Louisville, Kentucky, 40202, United States|START Midwest, Grand Rapids, Michigan, 49546, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|University of Wisconsin, Madison, Wisconsin, 53792, United States|Brussels - UNIV Saint-Luc, Bruxelles, 1200, Belgium|UZ Leuven, Leuven, 3000, Belgium|The Ottawa Hospital, Ottawa, Ontario, K1H 8L6, Canada|Rigshospitalet, K?benhavn, K?benhavn ?, 2100, Denmark|Helios Klinikum Berlin-Buch, Berlin, 13125, Germany|Universit?tsmedizin G?ttingen, Georg-August-Universit?t, G?ttingen, 37075, Germany|Universit?tsklinikum K?ln (A?R), K?ln, 50937, Germany|Universit?tsklinikum Tübingen, Tübingen, 72076, Germany|Sourasky Medical Center, Tel Aviv, 6423906, Israel|National Cancer Center Hospital, Tokyo, Chuo-ku, 104-0045, Japan|Severance Hospital, Seoul, 03722, Korea, Republic of|MED POLONIA SP Z O O, Clinical Trials Department,Poznan, Poznan, 60-693, Poland|Oncology Center-Maria Sklodowska-Curie Institute, Warsaw, 02-781, Poland|Hospital Vall d'Hebron-Barcelona-47683, Barcelona, 08035, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Fundación Jiménez Díaz, Madrid, 28040, Spain|Hospital Clínico de Santiago, Santiago de Compostela, 15706, Spain|Karolinska Comprehensive Cancer Center, Stockholm, 171 76, Sweden Less <<
NCT06058793 Liposarcoma, Dedifferentiated PHASE3 ACTIVE_NOT_RECRUITING 2025-11-30 University of Alabama at Birmi... More >>ngham, Birmingham, Alabama, 35249, United States|Mayo Clinic-Arizona, Phoenix, Arizona, 85054, United States|Precision NextGen Oncology, Beverly Hills, California, 90212, United States|Sarcoma Oncology Center, Santa Monica, California, 90403, United States|University of California Los Angeles, Santa Monica, California, 90404, United States|Yale Cancer Center, New Haven, Connecticut, 06510, United States|Mayo Clinic - Florida, Jacksonville, Florida, 32224, United States|University Cancer and Blood Center, Athens, Georgia, 30607, United States|Northwestern University, Chicago, Illinois, 60611, United States|University of Kansas Cancer Center, Overland Park, Kansas, 66210, United States|Mayo Clinic, Rochester, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|John Theurer Cancer Center, Hackensack, New Jersey, 07601, United States|Northwell Health, Lake Success, New York, 11042, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, 19106, United States|West Cancer Center & Research Institute, Germantown, Tennessee, 38138, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Utah Cancer Specialists Cancer Center, Salt Lake City, Utah, 84106, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Medical Oncology Associates, P.S., Spokane, Washington, 99208, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|Sanatorio Finochietto, Caba, C1120AAB, Argentina|Prince of Wales Hospital-Randwick-66496, Randwick, New South Wales, 2031, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia|Hospital do Cancer de Londrina, Londrina, 86015-520, Brazil|OncoClinicas Rio de Janeiro, Rio de Janeiro, 22250-040, Brazil|CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia, Santo André, 09060-650, Brazil|ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, 01246-000, Brazil|H.S.J. Beneficência Portuguesa - S?o Paulo, Sao Paulo, 01323-001, Brazil|A.C. Camargo, Sao Paulo, 01509-900, Brazil|Arthur J. E. Child Comprehensive Cancer Centre, Calgary, Alberta, T2N 5G2, Canada|BC Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, V8R 6V5, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|Aichi Cancer Center Hospital, Aichi, Nagoya, 464-8681, Japan|Nagoya University Hospital, Aichi, Nagoya, 466-8560, Japan|National Cancer Center Hospital East, Chiba, Kashiwa, 277-8577, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, 811-1395, Japan|Kyushu University Hospital, Fukuoka, Fukuoka, 812-8582, Japan|Tohoku University Hospital, Miyagi, Sendai, 980-8574, Japan|Okayama University Hospital, Okayama, Okayama, 700-8558, Japan|Osaka International Cancer Institute, Osaka, Osaka, 541-8567, Japan|Hokkaido Cancer Center, Sapporo, Hokkaido, 003-0804, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, 104-0045, Japan|Japanese Foundation for Cancer Research, Tokyo, Koto-ku, 135-8550, Japan|Addenbrooke's Hospital, Cambridge, CB2 0QQ, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|The Royal Marsden Hospital, Chelsea, London, SW3 6JJ, United Kingdom|The Christie, Manchester, M20 4BX, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.69mL

0.34mL

0.17mL

8.45mL

1.69mL

0.85mL

16.91mL

3.38mL

1.69mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories